Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 15Squamous Cell Carcinoma of Head and Neck 12Neoplasm Metastasis 12Prostatic Neoplasms 11Neoplasms 10Breast Neoplasms 8Stomach Neoplasms 7Recurrence 7Ovarian Neoplasms 7Myasthenia Gravis 7Lung Neoplasms 7Leukemia, Myeloid, Acute 7Head and Neck Neoplasms 7Colorectal Neoplasms 6Pancreatic Neoplasms 5Oropharyngeal Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Fatigue 5Urinary Bladder Neoplasms 4Mouth Neoplasms 4Melanoma 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Colonic Neoplasms 4Cholangiocarcinoma 4Rectal Neoplasms 3Peritoneal Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Glioblastoma 3

Interventions

Haloperidol 1Chlorpromazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Delirium × 90 days × Clear all
NCT03021486 2026-03-18

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
70 enrolled 20 charts

Delirium, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡